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Abstract
Background: Genetic classification of breast cancer based on the coding mRNA suggests the evolution
of distinct subtypes. Whether the non-coding genome is altered concordantly with the coding genome
and the mechanism by which the cell cycle directly controls the non-coding genome is poorly
understood.
Methods: Herein, the miRNA signature maintained by endogenous cyclin D1 in human breast cancer
cells was defined. In order to determine the clinical significance of the cyclin D1-mediated miRNA
signature, we defined a miRNA expression superset from 459 breast cancer samples. We compared the
coding and non-coding genome of breast cancer subtypes.
Results: Hierarchical clustering of human breast cancers defined four distinct miRNA clusters (G1-G4)
associated with distinguishable relapse-free survival by Kaplan-Meier analysis. The cyclin D1-regulated
miRNA signature included several oncomirs, was conserved in multiple breast cancer cell lines, was
associated with the G2 tumor miRNA cluster, ERα+ status, better outcome and activation of the Wnt
pathway. The coding and non-coding genome were discordant within breast cancer subtypes. Seed
elements for cyclin D1-regulated miRNA were identified in 63 genes of the Wnt signaling pathway
including DKK. Cyclin D1 restrained DKK1 via the 3’UTR. In vivo studies using inducible transgenics
confirmed cyclin D1 induces Wnt-dependent gene expression.
Conclusion: The non-coding genome defines breast cancer subtypes that are discordant with their
coding genome subtype suggesting distinct evolutionary drivers within the tumors. Cyclin D1
orchestrates expression of a miRNA signature that induces Wnt/β-catenin signaling, therefore cyclin D1
serves both upstream and downstream of Wnt/β-catenin signaling.
Key words: cyclin D1, miRNA, breast cancer

Introduction
The cyclin D1 (CCND1) gene encodes the
regulatory subunit of a holoenzyme that phosphory-

lates and inactivates the Rb protein to promote DNA
synthesis [1]. Cyclin D1 is overexpressed in up to 50%
http://www.thno.org
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of human breast cancers. Cyclin D1 is required for the
growth of cultured breast cancer cells and is necessary
for the growth of oncogene-induced breast tumors in
mice [2, 3]. The prognostic significance of cyclin D1
expression in human breast cancer epithelial cells has
been carefully studied and correlates with ERα+
breast cancer and better patient outcome [4-6]. The
common finding of cyclin D1 overexpression in the
majority of human breast cancers is a consequence of
gene amplification, reduced degradation or enhanced
gene expression via oncogenic signals, including Ras,
ErbB2 and Wnt/β-catenin signaling [7]. In addition,
cyclin D1 contributes to the phosphorylation of other
substrates including NRF1 in order to coordinate
diverse activities within the cell, including the
inhibition of mitochondrial metabolism and the
phosphorylation of transcription regulatory factors [8,
9]. The DNA-bound form of cyclin D1 regulates gene
expression through the recruitment of transcription
factors [10, 11] and histone regulatory enzymes, in the
context of local chromatin [10, 11]. The recruitment of
histone deacetylase (HDAC1/HDAC3), histone
acetylase (p300/CBP) and chromatin remodeling
protein (SUV39, HP1α) [11] contributes to the
alterations in gene expression of the coding genome
[12, 13]. Both androgen- [14] and estrogen- [15]
regulated growth factor gene expressions require
cyclin D1 in vivo [7].
In addition to regulating the coding region,
cyclin D1 has been shown to regulate non-coding
miRNA [16]. The miR-17-20 locus is induced by cyclin
D1, correlating with an association of cyclin D1 in the
context of local chromatin within the microRNA
regulatory region [16]. MicroRNAs (miRNAs) are a
class of endogenous non-coding small RNAs
participating in diverse biological processes through
base-pairing to the complementary sequence in the 3’
untranslated region (3’ UTR of mRNA). Two
complementary short RNA molecules are formed
from stem-loop-stem pre-miRNA by Dicer cleavage,
but only mature miRNA can integrate into the
RNA-induced silencing complex (RISC) to regulate
target mRNA expression. miRNA abundance is
regulated in response to cellular signaling during cell
cycle transition and cyclin D1 has been shown to
govern miRNA processing through the induction of
Dicer [17]. An alteration in miRNA expression is
thought to contribute to the timing of cell-cycle
transition, cell proliferation, stem cell self-renewal,
cancer onset and progression [18]. An association of
specific miRNA with initiation, progression and
therapy resistance in human breast cancer has been
demonstrated [19, 20]. The molecular mechanisms
coordinating patterns of miRNA expression are
poorly understood but are considered important for
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targeted therapies, in particular for therapy-resistant
breast cancer [19]. In this regard, the let-7 and
miR-17-20 cluster is induced by estrogen [21] and
let-7f contributes to aromatase inhibitor resistance
through repressing the aromatase promoter [22]. The
miRNA cluster C19MC member miR-519a was
identified to be the most highly upregulated miRNA
in tamoxifen-resistant MCF-7 cells [23]. miR-519a
overexpression increased viability and the S-phase
population
and decreased tamoxifen-induced
apoptosis [23].
The multiple distinct mechanisms regulating the
Wnt pathway are critical for the fine-tuning of
signaling that occurs during physiological and
biological processes. Disruption of these constraining
influences occurs in human malignancies including
breast cancer. Activation of the Wnt/β-catenin
pathway in human breast cancer contributes to
cellular proliferation, in part through the induction of
cyclin D1 [24-26]. The canonical Wnt/β-catenin
pathway is induced by Wnt ligands that bind to
receptors including Frizzled (Fzd) [27] and the LDL
receptor-related proteins 5 or 6 (LRP5, LRP6) [28]. The
cytoplasmic protein Dishevelled (Dvl) is phosphorylated and thereby dissociates from a destruction
complex, which includes AXIN, adenomatous
polyposis coli (APC), casein kinase 1α (CK1α) and
glycogen synthase kinase 3β (GSK3β). The stabilized
β-catenin translocates to the cell nucleus to form a
transcriptional complex with β-catenin LEF/TCF,
thereby inducing downstream gene expression.
Several pathways antagonize β-catenin signaling. The
Dickkopf WNT signaling pathway inhibitor (DKK)
proteins are antagonists of the WNT signaling
pathway. DKKs function by isolating the LRP6
co-receptor so that it cannot support the WNT
signaling pathway [29] and via a reduction in
β-catenin abundance [30]. Although it is known that
cyclin D1 is a downstream target of Wnt signaling, the
notion that cyclin D1 functions upstream of Wnt
signaling remains to be determined [24-26].
Given the importance of cyclin D1 in breast
cancer, the current studies were conducted in order to
generate a comprehensive analysis of the miRNA
regulated by endogenous human cyclin D1 in breast
cancer cells. The cyclin D1-regulated microRNA
signature was associated with ERα positive breast
tumors and activation of the Wnt pathway. The cyclin
D1-mediated miRNA signature engages a network of
coding genes, including DKK, that govern Wnt
signaling. Thus in addition to serving as a
down-stream target of Wnt/β-catenin, cyclin D1
governs an additional regulatory mechanism that
activates Wnt via non-coding miRNA.

http://www.thno.org
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Results
Cyclin D1 induces oncogenic miRNA
abundance in breast cancer cell MCF-7. Cyclin D1 is
overexpressed in up to 50% of human breast cancers
and was previously shown to regulate miR-17-20
expression in breast cancer [16]. In order to define a
comprehensive analysis of the miRNA regulated by
cyclin D1 in human MCF-7 breast cancer cells,
quantitative real-time RT-PCR-based miRNA analysis
was conducted comparing the miRNA expression
profiles in MCF-7 cells or MCF-7 cells treated with
cyclin D1 siRNA (Figure 1A, B). Among 742 examined
miRNAs, ~500 were detectable with ~30% showing
>1.5-fold reduced expression in cyclin D1 knock-down
cells (Figure 1C). In contrast, miR-21, the most
abundant miRNA in MCF-7 cells, was not
significantly regulated by endogenous cyclin D1. The
fold change in expression (Cyclin D1+ vs. Cyclin D1-) of
representative miRNAs is shown in Figure 1D, and
further confirmed using QRT-PCR as shown in Figure
1E. The cancer-related miR-17-92 cluster (Figure S1A)
and its paralogs (Figure S1B, C) were induced by
endogenous cyclin D1. The Oncomir C19MC cluster
[31], including miR-517c, 518d, 518c, 518f, 519, 525,
was also induced by endogenous cyclin D1 (Figure
S1D). In addition, members of the let-7 miRNA family
were reduced by cyclin D1a siRNA (Figure S1E, F). In
order to determine the miRNA signature of cyclin D1
in other breast cancer cell lines, representative
miRNAs were analyzed in Hs578t cells (Figure S2). In
Hs578t cells, 10 of the 15 miRNA were reduced by
cyclin D1 siRNA, suggesting significant conservation
of regulatory mechanisms between breast cancer cell
lines.
Classification of human breast cancers by their
miRNA expression profiles. Emerging evidence has
demonstrated miRNA involvement in human cancers
including breast cancer [19, 20]. In order to determine
the functional significance of the cyclin D1-regulated
miRNA expression profile, a compendium of breast
tumor miRNA was generated from multiple miRNA
expression datasets that were associated with clinical
information (Figure 2A). The compendium consisted
of 114 miRNAs (Table S1) measured in 459 tumors
(Figure 2A). Of these, 265 tumors were associated
with estrogen receptor status, 308 tumors were
associated with tumor grade, 175 tumors were
classified using mRNA expression profiles of
molecular subtypes and 249 tumors were linked with
time to relapse data. We used this data to classify
tumors using hierarchical clustering to identify four
clusters of tumors (referred to as G1-4; Figure 2A) on
the basis of expression of all miRNAs in the
compendium. In order to determine the pathological
significance of miRNA expression profiles, we
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evaluated the association of these miRNA subtypes
with relapse-free survival (Figure 2B). Kaplan-Meier
analysis indicated that tumors in groups G1 and G2
have relatively good prognosis whereas tumors in
groups G3 and G4 have poor prognosis. In addition, a
significant difference was detected in the risk of
relapse between the four groups (p = 0.04).
Cox-regression analysis verified that tumors in the G4
group have significantly higher risk of relapse than
tumors in groups G1 and G2 (Figure 2B). The findings
suggest that miRNA expression profiles are
associated with differences in prognosis in breast
cancer.
The cyclin D1-regulated miRNA signature
correlated with ERα positive, low grade tumors and
better outcome for breast cancer. We investigated the
clinical significance of the cyclin D1-regulated miRNA
signature identified in breast cancer cells by
examining associations with clinical covariates,
including breast cancer-associated miRNA, ERα
status, tumor grade and molecular genetic subtype
(coding genome), and relapse-free survival using the
breast cancer miRNA compendium. The cyclin D1
miRNA signature consists of 121 miRNAs (Table S2)
that are upregulated by 2-fold or more in cyclin D1+
vs. cyclin D1- cells (Figure 1). 26 of the cyclin
D1-regulated miRNA displayed corresponding
regulation in breast cancer patients (Figure 3A, Figure
S3 and Figure S4). The cyclin D1-regulated 26
cancer-associated miRNA signature was assessed for
clinical covariates. First, we calculated expression of
the cyclin D1-regulated miRNA signature as the
average expression of these miRNA in each tumor in
the compendium. We next sorted the tumors based on
these expression values. We compared the
distributions of the cyclin D1 miRNA signature in sets
of tumors classified by clinical covariates using
non-parametric statistical testing. Notably, high
expression of the cyclin D1 miRNA signature was
associated with the good prognosis cluster G2 (Figure
3B; p = 3.7×10-7). In contrast, low expression of the
cyclin D1 miRNA signature was associated with the
poor prognosis cluster G4 (Figure 3B; p = 9.2×10-3).
The cyclin D1 miRNA signature was positively
associated with ERα+-status and negatively associated
with poor outcome histological grade. The cyclin
D1-regulated miRNA were expressed at a higher level
in ERα+ positive relative to ERα- disease (Figure 3C, p
= 0.03; Figure S5). Similarly, cyclin D1-regulated
miRNA were downregulated in tumors with high
histological grade (Figure 3D, p = 0.007; Figure S6). In
contrast, the association with the molecular genetic
subtype and the cyclin D1-regulated miRNA
signature was not statistically significant (Figure 3E,
Figure S7).
http://www.thno.org
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Figure 1. Cyclin D1 induces a miRNA signature. (A) Schematic representation of the procedure in which MCF-7 cells were treated with control or cyclin D1
siRNA knockdown. (B) Western blot analyses showing the decreased level of cyclin D1 by siRNA. (C) The pie chart shows the percentage of miRNA with
expressions altered by cyclin D1 siRNA and their fold change in abundance. (D) Graphical representation showing the distribution of the log2 (control vs. cyclin D1
siRNA) of miRNA expression in MCF-7 cells. Shadowing represents the miRNAs reduced (green) and induced (red) more than 1.5-fold by endogenous cyclin D1. (E)
Validation of representative miRNAs’ expression in MCF-7 cells treated with negative control or cyclin D1 siRNA; the results are shown as mean ± SEM (n=3).

Together, these studies demonstrate that the
cyclin D1-regulated miRNA signature correlates with
ERα positive tumors, better tumor grade and better

prognosis. These findings are consistent with
observed associations between expression of cyclin
D1 and clinical covariates in breast cancer.
http://www.thno.org
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Figure 2. Classification of breast tumors by miRNA expression profiling distinguishes good and poor prognosis tumors. (A) miRNA expression
profiles and clinical information from the breast cancer compendium. Rows indicate expression of 114 miRNA. Columns indicate expression of miRNA in 459 breast
tumors compiled from four datasets. Green points represent down-regulation, red points represent up-regulation. Rows and columns were sorted using hierarchical
clustering with Pearson correlation and average linkage. Hierarchical clustering was used to classify tumors into four groups according to their miRNA expression
profiles (G1 = green, G2 = orange, G3 = blue, G4 = pink, outliers = black). Column color bars indicate the clinical data associated with each sample. (B) Kaplan-Meier
plot of relapse-free survival in breast cancer for miRNA subtypes.

http://www.thno.org
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Figure 3. Expression of the cyclin D1-regulated miRNA signature is associated with biological features and clinical outcomes in breast cancer.
(A) Venn diagram indicating the number of miRNA in the ‘cyclin D1 signature” (miRNA regulated by cyclin D1), the number of miRNA measured in the breast cancer
compendium and the intersection of these sets. (B) Distribution of cyclin D1 miRNA signature in breast tumors classified by miRNA subtype. Hashmarks below the
plot indicate the expression of the cyclin D1-regulated miRNA for each tumor. Color indicates the miRNA subtype of the associated set of tumors. High expression
of the cyclin D1 miRNA signature is associated with G2 (p = 3.7×10-7). Low expression of the cyclin D1 miRNA signature is associated with G4 (p = 9.2×10-3). (C)
Cyclin D1-regulated miRNA signature in tumors classified by estrogen receptor (ERα) status. Hashmarks below the plot indicate the expression of the cyclin D1
miRNA signature for each tumor. Color indicates the estrogen receptor status of the associated set of tumors. High expression of the cyclin D1 miRNA signature is
associated with ERα-positive disease (p = 0.03). (D) Cyclin D1-regulated miRNA signature in tumors classified by histological grade. Low expression of the cyclin D1
miRNA signature is associated with grade 3 (p = 0.007). (E). Cyclin D1 miRNA signature in tumors classified by molecular genetic (coding genome) subtype.

The cyclin D1 miRNA signature intersects Wnt
signaling. In order to investigate further the
biological significance of the cyclin D1-mediated
miRNA signature in breast cancer, we performed a
target gene screening and pathway analysis to the 26
miRNA signature regulated by endogenous cyclin D1
in breast cancer. Alignment of the cyclin D1-regulated
breast cancer-associated miRNA signature with gene
sequences identified 63 genes in the Wnt pathway
potentially targeted by the miRNA signature (Figure
4A). KEGG pathway analysis identified enrichment
for signaling pathways involved in breast cancer
regulation including Wnt signaling pathway (p =
0.048, Figure 4B). The increased DKK1 and decreased
Wnt5A expression were associated with knockdown
of cyclin D1 in MCF-7 cells (Figure 4C). Because the
Wnt signaling inhibitor DKK1 was found to be
targeted by multiple cyclin D1-regulated miRNAs
(Figure 4A), a reporter plasmid carrying the 3’UTR of

DKK1 was applied to cyclin D1-overexpressing cells,
showing ~20% inhibition of DKK1 by cyclin D1 in
MCF-7 cells (Figure 4D, E). We hypothesized that
cyclin D1-regulated miRNAs, including miR-34a and
miR-148, suppressed DKK1 expression. A comparison
was therefore made between the DKK1 3’UTR and a
DKK1 3’UTR reporter with point mutations in the
miR-34 and miR-148 binding sites, linked to a
luciferase reporter vector (Figure 4F). Cyclin D1
siRNA upregulated the DKK1 WT 3’UTR, but did not
regulate the DKK1 3’UTR that was mutated in the
miR-34 and miR-148 binding site (Figure 4G). In
addition, enforced overexpression of miR-34 or
miR-148a suppressed the DKK1 WT 3’UTR reporter,
but failed to repress the DKK1 mutated 3’UTR (Figure
4H, I and Figure S8). Together these studies provide
further support for a model in which the cyclin
D1-regulated miRNAs contribute to Wnt signaling
regulation by cyclin D1 in MCF-7 cells.
http://www.thno.org
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Figure 4. Cyclin D1-regulated miRNAs govern the Wnt signaling pathway. (A) Interaction between cyclin D1-regulated miRNAs and target mRNAs in the
Wnt signaling pathway. The y-axis shows Wnt signaling pathway genes that are predicted targets of the cyclin D1-regulated miRNA. The x-axis shows cyclin
D1-regulated miRNAs in MCF-7 cells. Black boxes indicate predicted interactions between the gene and miRNA. Both axes were ordered using (pseudo-) hierarchical
clustering. (B) Signaling pathways potentially targeted by cyclin D1-regulated miRNAs (p < 0.05) in MCF-7 cells. (C) Upregulation of DKK1 and downregulation of
Wnt 5A were associated with cyclin D1 knockdown by siRNA in MCF-7 cells. (D) Schematic representation of the Luciferase reporter carrying DKK1 3’UTR. (E) The
DKK1 3’UTR activity is suppressed by cyclin D1 in MCF-7 cells. (F) Sequencing alignment indicated that DKK1 3’UTR has binding sites to multiple cyclin D1-regulated
miRNAs including miR-34 and miR-148a. Point mutations to the binding sites were applied to demonstrate the direct interaction between the 3’UTR of DKK1 and
miR-34/miR-148a. (G) Luciferase reporter assays indicated that WT DKK1 3’UTR activity was inhibited by endogenous cyclin D1 in MCF-7 cells, but not the mutated
DKK1 3’UTR. (H, I) Luciferase reporter assays are shown as mean ± SEM (n=3). miR-34 or miR-148a overexpression inhibited WT DKK1 3’UTR activity, but not
mutated DKK1 3’UTR.

http://www.thno.org
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Cyclin D1-mediated regulation of the Wnt signal
transduction pathway was assessed in MCF-7 cells
using cyclin D1 siRNA, and the surrogate TCFresponsive luciferase reporter (TOP-LUC). TOP-LUC
activity, compared with the TCF-mutant reporter
(FOP-LUC), was increased 80% by endogenous cyclin
D1 (Figure 5A). Consistent with the repression of the
DKK1 3’ UTR by cyclin D1, and the identification of
binding sites for miR-34 and miR-148 in the DKK1 3’
UTR, cyclin D1 was shown to induce these miRNAs in
MCF-7 cells (Figure 1E and Figure S9). In order to
determine whether acute induction of cyclin D1 was
sufficient to induce Wnt-mediated gene expression in
vivo, transgenic mice were employed. Tetracycline
was used to induce the cyclin D1 transgene and after 1
week the mammary glands were harvested. The
induction of the mammary epithelial cell
(MEC)-targeted cyclin D1 transgene for one week was
sufficient to induce Wnt signaling pathway genes
including Smad, Rock, Fzd and others (Figure 5B).
Consistent with the DKK reporter studies, induction
of the cyclin D1 transgene reduced expression of the
Wnt signaling pathway inhibitors DKKs and Prickle
(Figure 5B).
In order to examine the possibility that the
abundance of cyclin D1 may be negatively correlated
with DKK1, we examined mRNA expression from the
TCGA database. Analysis was conducted of 1,085
breast cancer patients and 291 normal control
samples. As shown in Figure 5C, upregulation of
cyclin D1 and Wnt5A and downregulation of DKK1 in
breast cancer samples were observed compared to
normal control. In addition, the expression of cyclin
D1 was positively correlated with Wnt4 and Wnt5A
but negatively correlated with DKK1 expression in
breast cancer patients (Figure 5D).
In order to examine potential mechanisms by
which cyclin D1 regulated miRNA expression herein,
we considered two previously characterized
processes. Firstly, in this regard, cyclin D1 has been
shown to regulate gene transcription via binding in
the context of chromatin to either repress or induce
gene expression [7, 32]. Cyclin D1 has also been
shown to selectively regulate miRNA expression at
the transcriptional level through binding to the
promoter region of miRNAs [14]. ChIP-sequence
analysis demonstrated that within the cyclin
D1-regulated miRNA signature, cyclin D1 was
recruited to the regulatory region of miR-216a, 26b,
298 and 34a (Figure 6A). A second mechanism by
which cyclin D1 regulates miRNA involves Dicer. Our
previous work has demonstrated the cyclin D1
induction of Dicer promotes miRNA biogenesis [17].
In addition to miRNA biogenesis, Dicer itself
contributes to the regulation of miRNA expression, as
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the Dicer-/- cells have altered expression of specific
miRNA [33]. We therefore compared the miRNA
expression profile regulated by Dicer, and the miRNA
expression profile regulated by cyclin D1. They
showed similar miRNA expression patterns. The
miRNA miR-10a, let-7d, miR-34c, miR-193* and
miR-202, were regulated both by Dicer and by cyclin
D1 (Figure S10, Table S2).
Taken together these data show that cyclin D1
induces expression of miRNA (miR-34 and miR-148a)
that restrains DKK1 via its 3’ UTR through seed
elements for miR-34 and miR-148a. Cyclin D1
regulates miRNA expression either through Dicer or
through regulating miRNA promoter expression
(Figure 6B).

Discussion
The current studies identified several novel
findings illustrating an important role of cyclin D1 in
maintaining the abundance of miRNA that govern
Wnt signaling. Firstly, we show that cyclin D1
maintains a specific cluster of miRNA in human
breast cancer cells. Secondly, we showed that the
cyclin D1-mediated miRNA expression profile was
concordant with the direction of expression of ~25%
of the breast cancer-associated miRNA. Thirdly, this
miRNA signature had specific biological correlates:
correlated with ERα+ breast cancer, anti-correlated
with poor outcome and highly correlated with Wnt
signaling. Fourthly, the cyclin D1-mediated miRNA
expression profile correlated highly with a matrix of
cyclin D1-mediated miRNA identified target 3’ UTR
sequences in the known Wnt target genes. Evidencing
the significance of cyclin D1 in Wnt signaling, DKK1,
a repressor of Wnt signaling, was repressed by
endogenous cyclin D1, and expression of a cyclin D1
transgene in the mammary gland of transgenic mice
induced expression of Wnt-related gene expression.
Emerging
evidence
has
demonstrated
interactions between cyclin D1 and miRNAs (miR-17/
20, let-7 and miR-15/16) in control of human cancer
[16, 34, 35]. The current studies demonstrated that
cyclin D1 enhanced the expression of several
onco-miRNAs. The miR-17-92 cluster of miRNAs on
human chromosome 13 and its cluster paralogs
(miR-106b-25, on chromosome 7) and the
miR-106a-363 cluster on the X chromosome are
known to act as oncogenes [36]. The miRNAs induced
by cyclin D1 included the oncomiR miR-17-20 and all
of its paralogs [36] (Figure S1). Components of a
miRNA polycistron (miR-506, 513a, 518f, 519d, 520b
and 524) [37], which are amplified in tumors [38] and
contribute to tamoxifen resistance, were induced by
cyclin D1. It is of interest that every miRNA of the
oncomiR clusters was induced by cyclin D1. The cyclin
http://www.thno.org
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D1 gene undergoes alternative splicing, resulting in
two distinct isoforms encoding alternate carboxyl
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terminus C, with distinct properties in the DNA
damage response and cell migration [39, 40].

Figure 5. Cyclin D1 activated Wnt signaling in the mammary gland in vivo. (A) Schematic representation of the TOP-LUC and Tcf site mutant reporter
(FOP-Luc). Tcf activity was assessed in MCF-7 cells using the Top-Flash-Luc reporter, with activity shown as mean ± SEM. The assays indicate higher Wnt signaling
activity in cyclin D1+ MCF-7 cells compared with cyclin D1- MCF-7 cells. (B) Schematic representation of the tetracycline-inducible mammary gland epithelial
cell-targeted cyclin D1a transgenic mice. Mammary gland mRNA was analyzed after 1 week from three transgenic mice. The expression and p value of Wnt signaling
pathway genes regulated by the transgene are shown. (C) TCGA analysis showed the upregulation of cyclin D1 and Wnt 5A and downregulation of DKK1 in 1085
breast cancer patients compared to 291 normal control samples. (D) TCGA analysis showed the positive correlation between cyclin D1 and Wnt 4/Wnt 5A
expression, and negative correlation between cyclin D1 and DKK1 expression in breast cancer patients.

http://www.thno.org
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Figure 6. (A) ChIP of cyclin D1 followed by ChIP sequencing (ChIP-Seq) indicated the binding of cyclin D1 on the promoter region of indicated miRNAs that
were identified within the cyclin D1-regulated miRNA signature. (B) Schematic representation of the mechanisms through which cyclin D1 induces tumorigenesis in
breast cancer by repression of DKK1 and induction of Wnt signaling, which is at least partly mediated by miRNAs.

The current studies conducted hierarchical
clustering of miRNA from 459 breast cancers and
thereby identified 4 distinct types of breast cancer
with distinct survival outcomes, G1 being favorable
and G4 associated with poor outcome. A comparison
between miRNA-based classification and mRNAbased classification of the same tumors evidenced
only moderate overlap with some enrichment of the
basal mRNA expression subtype amongst the G4
miRNA subtype. The cyclin D1-mediated miRNA
signature was correlated with the G2 subtype and
anti-correlated with the G4 subtype. Together these
findings suggest independent drivers or independent
evolution of the miRNA vs. mRNA expression within
an individual patient’s breast cancer.
Herein the miRNA induced by cyclin D1 were
shown to align with the seed sequences in the 3’ UTR
of essentially all known genes of the Wnt pathway.
Consistent
with
cyclin
D1
activating
the
Wnt/β-catenin signaling pathway, a surrogate
measurement of this pathway’s activity in reporter
gene assays, TCF activity was maintained by
endogenous cyclin D1 in breast cancer cells.
Furthermore, acute induction of a cyclin D1 transgene
induced Wnt activity in vivo as assessed by TCF4 IHC
in the murine mammary gland. In the current studies,
cyclin D1-regulated miRNAs were predicted to
induce a broad array of Wnt-activating components
(Wnt1, Wnt3a, Wnt5A, Wnt10b, Wnt16, Vangl2,

SIAH1, PP2A) and restraining components governing
Wnt repression (Prickle 2, DKK1,2,4). In addition to
the description of Wnt signaling above, the
canonical Wnt pathway involves degradation of
β-catenin by a β-TrCP1-containing E3 ligase, and
alternative β-catenin degradation mediated by
SIAH-1 (seven in absentia homolog-1) is responsible
for the effect of CSN5 on β-catenin signaling [41].
Cross-talk occurs with other pathways including the
PI3K/AKT [42, 43]. Active β-catenin is induced by the
PI3K pathway and is dependent on the phosphatase
activity of the protein phosphatase PP2A [43]. ERK
phosphorylation of GSK3β is induced by IGF and
TGFβ. ERK phosphorylates GSK3β at the Thr 43
residue, which primes GSK3β for its subsequent
phosphorylation at Ser9 by p90RSK, resulting in
inactivation of GSK3β and upregulation of β-catenin
[42]. Vangl2, a core component in planar cell polarity,
forms a Wnt-induced receptor complex with Ror2 to
sense Wnt dosages [44]. Wnt signaling is retrained by
DKK, and the 3’ UTR of DKK1 is repressed by cyclin
D1. Tumor suppression by PTEN and p27KIP1 involves
restraint of β-catenin activity [45]. Cyclin D1 is a target
of β−catenin/ TCF signaling [24] and β-catenin is a
marker of poor prognosis in breast cancer [26]. In
recent studies, cyclin D1 was shown to induce clusters
of mRNA that govern Wnt/β-catenin transcriptional
pathways [46]. Endogenous cyclin D1 enhanced Wnt and ES cell gene expression and
http://www.thno.org
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expanded a prostate stem cell population. In these
prior studies using chromatin immunoprecipitation
sequencing, cyclin D1-occupied genes were found to
govern stem cell expansion and induce their
transcription. The current studies extend our
understanding of cyclin D1, known to be a
downstream target of Wnt/β-catenin signaling, by
showing cyclin D1-induced miRNA clusters that
engage the Wnt pathway.

Methods and Materials
Transgenic mice. Cyclin D1-/- mice were
maintained in our lab on a mixed C57B1/6x129/SvJ
background. The tetracycline-inducible mammary
epithelial cell-targeted cyclin D1a transgenic mice
established in the FVB strain (MMTV-rtTA-cyclin D1a
transgenic mice) were previously described [47]. Eight
to ten-weeks-old female mice was used for in vivo
experiments. All mouse experiments were done in
accordance with the guidelines for the care and use of
laboratory animals at Thomas Jefferson University.
Cell culture. MCF-7 and Hs578T cells were
originally from ATCC and were maintained in our
laboratory. Cells were cultured in DMEM containing
penicillin and streptomycin (100 mg of each/L) and
supplemented with 10% fetal bovine serum (FBS).
siRNAs and transfection. All siRNAs were from
Qiagen. The target sequence for cyclin D1 was
AACAAGCTCAAGTGGAACCTG.
The
target
sequence for the negative control siRNA was
AATTCTCCGAACGTGTCACGT.
Lipofectamine
RNAiMax (Invitrogen) was used to transfect siRNA
into cells following the manufacturer’s instructions.
miRNA expression profiling and data analysis.
Human miRNAs in cyclin D1 siRNA-treated MCF-7
cells and MCF-7 control cells were profiled in
triplicate using the Exiqon microRNA Ready-to-Use
PCR Human panel I+II (Product no:203607) and
miRCURY LNATM Universal cDNA Synthesis Kit
(Product no:203300) following the Manufacturer’s
instructions. miRNA expression measurements were
estimated using the delta-delta Ct method. The set of
miRNAs regulated by cyclin D1 was identified using
a differential expression fold change threshold of 2.0
for comparison with the miRNA expression database
in breast tumors. For the target gene prediction and
pathway analysis, a threshold for significance as
p<0.05 was applied to the above miRNA set regulated
by cyclin D1. Predicted gene targets for the miRNAs
were identified using the miRdbv4.0 (http://mirdb
.org/miRDB/). These predicted targets were
compared with the KEGG Wnt signaling pathway
genes obtained from the KEGG pathway database
(http://www.genome.jp/kegg/kegg2.html).
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Gene reporter assays. The WT and mutated
DKK1-3’UTR luciferase reporter vectors were created
in our lab. The TOP-LUC / FOP LUC reporters were
previously described [25]. For cellular transfection
with reporter DNA, actively growing cells were
seeded on 12-well plates at a density of 1×105
cells/well. The next day, cells were co-transfected
using lipofectamine 2000 (Invitrogen) with 0.5 µg of
Luc vector and 0.1 µg of CMV/ß-galactosidase
plasmid. Twenty-four hours after transfection,
luciferase activities were measured by AutoLumat
and normalized with ß-galactosidase.
Compilation of miRNA expression data across
platforms. Four datasets of microRNA expression
profiles of breast tumors linked to corresponding
clinical data were collected from the ArrayExpress
database (ArrayExpress Identifiers: E-GEOD-22220,
E-GEOD-7842, E-GEOD-19783, E-GEOD-15885) [20,
48-51]. In addition to expression data, sample
annotation information and array design information
were obtained in the form of ArrayExpress .sdrf and
.adf files, respectively. Pre-processed data was used if
available. If pre-processed data was not available, raw
data was normalized by: calculating an average value
for foreground and background intensity of replicate
spots mapping to the same miRNA, log2
transformation of foreground and background
signals, background correction by subtracting the
background signal from each foreground signal,
thresholding to set missing expression values to an
arbitrary low value (0.1), and quantile normalization.
In order to identify common features across array
platforms, miRNA probes were mapped to the
mirbase mature miRNA accession identifier [52]. For
array platforms annotated with sequence information,
an exact match of the target sequence to the mirbase
sequence was used to ensure accurate annotation.
Array platforms without sequence information were
incorporated only when the specific release of the
mirbase database used for platform design was
reported. For these platforms, miRNA name was used
for annotation based on the corresponding mirbase
release. Cross-platform normalization was used to
estimate
and
minimize
the
effects
from
dataset-specific noise. In this process, arrays are
filtered to obtain expression data associated with the
phenotype of interest. Following array filtering,
datasets are transformed from probe set space to
miRNA space by calculating the median expression
value of all probes mapping to a given miRNA. Next,
miRNA are filtered to retain only the miRNA that are
represented on all array platforms. Array-filtered,
transformed and miRNA-filtered data is normalized
across platforms using the XPN algorithm [53]
implemented with the CONOR package [54] in the R
http://www.thno.org
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Statistical Environment. Data summarization plots,
including
boxplots,
two-dimensional
PCA
projections, and hierarchical clustering were used for
quality control of cross-platform normalization to
ensure good mixing of data across platforms.
Evaluation of clinical relevance of cyclin
D1-regulated miRNA. The clinical implications of
cyclin D1-mediated miRNA expression were
investigated by examining the association between
cyclin D1-regulated miRNA and clinical covariates.
Cyclin D1-regulated miRNA were identified as
described above. A signature of cyclin D1 activity in
clinical tumor samples was obtained based on the
expression profile of the cyclin D1-regulated miRNA.
Expression data was median centered such that tumor
expression profiles reflected the expression of a given
miRNA relative to the average expression of the
miRNA across all tumors. The value of the cyclin
D1-mediated miRNA expression signature for each
tumor was determined by calculating the average
expression of cyclin D1-regulated miRNA in each
tumor. Tumors were then sorted according to
expression of the cyclin D1-mediated miRNA
expression signature and association with clinical
covariates was tested using non-parametric statistical
hypothesis testing. Association with relapse-free
survival was assessed by first classifying tumors on
the basis of miRNA expression, calculating the
association of cluster membership with relapse-free
survival and calculating the association between the
cyclin D1-mediated miRNA expression signature and
the miRNA clusters. Clusters were defined using
hierarchical clustering using Pearson correlation and
average linkage. The first two major bifurcations of
the sample dendrogram (excluding two small clusters
of outliers) were used to identify miRNA clusters. Cox
proportional hazards analysis was used to associate
miRNA clusters with
relapse-free survival.
Association of the cyclin D1-mediated miRNA
expression with miRNA clusters was determined as
described above.
TCGA database analysis. The GEPIA web
server [55] was used to analyze the gene expression
levels of cyclin D1, DKK1 and Wnt A in 1,085 breast
cancer patients vs. 291 normal samples from TCGA
and GTEx databases. The Pearson Correlation
Coefficient was used to determine the strength of the
relationship between cyclin D1 and Wnt signaling
factors. Non-log scale for calculation and log-scale
axis for visualization were applied.
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